Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT04866056

Collaborator

(none)

Enrollment

Arm

15.9

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.

Condition or Disease	Intervention/Treatment	Phase
Myelodysplastic Syndromes Myeloproliferative Neoplasms Myelofibrosis	Drug: Jaktinib Drug: azacitidine	Phase 1/Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

56 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Multicentric Phase I/II Study of Jaktinib Hydrochloride Tablets in Combination With Azacitidine for Injection in Patients With Myelodysplastic Syndromes(MDS) With Myelofibrosis(MF) or MDS/Myeloproliferative Neoplasms With MF

Anticipated Study Start Date :

Jan 1, 2022

Anticipated Primary Completion Date :

May 1, 2023

Anticipated Study Completion Date :

May 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment(Jaktinib+Azacitidine) Patients receive azacitidine subcutaneously (SC) on days 1-7 and Jaktinib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Drug: Jaktinib Jaktinib PO BID Drug: azacitidine Azacytidine SC

Arm

Intervention/Treatment

Experimental: Treatment(Jaktinib+Azacitidine)

Patients receive azacitidine subcutaneously (SC) on days 1-7 and Jaktinib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: Jaktinib

Jaktinib PO BID

Drug: azacitidine

Azacytidine SC

Outcome Measures

Primary Outcome Measures

Objective response rate (complete remission+partial remission+marrow compete remission +cytogenetic complete remission + hematological improvement) in patients with Myelodysplastic Syndromes [Up to16 weeks]
According to the 2006 International Working Group (IWG) response criteria in myelodysplasia，The objective response rate will be estimated along with the Bayesian 95% credible interval.
Objective response rate (complete remission+cytogenetic complete remission+partial remission+clinical improvement) in patients with myelodysplastic syndromes/myeloproliferative neoplasms [Up to16 weeks]
According to the 2015 ICP in MDS/MPN. The objective response rate will be estimated along with the Bayesian 95% credible interval.

Secondary Outcome Measures

Overall survival [Time from treatment start till death or last follow-up, assessed up to 2 years]
Will be listed and summarized by the Kaplan-Meier estimator
Duration of response [Duration from the first documented onset of partial response or complete response to the date of progressive disease/relapse, assessed up to 2 years]
Will be listed and summarized by the Kaplan-Meier estimator
Relapse-free survival [Time from start of response to the date of event defined as the first documented progressive disease/relapse or death, whichever comes first, assessed up to 2 years]
Will be listed and summarized by the Kaplan-Meier estimator

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subjects voluntarily sign the informed consent form (ICF);
Age ≥ 18 years, either male or female;
Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
Expected life expectancy is greater than 24 weeks;
Diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) according to World Health Organization (WHO)；
The patients understands the purpose of and procedures required for the study and is willing to participate in the study；

Exclusion Criteria:

Subjects with congestive heart failure, uncontrolled or unstable angina or myocardial infarction,cerebrovascular accident, or pulmonary embolism within 6 months prior to screening;
Subjects suffering from arrhythmia and requiring treatment, or QTcB > 480ms at screening;
Subjects with clinical symptoms of active bacterial, viral, parasitic or fungal infections requiring treatment at screening;
Subjects with known human immunodeficiency virus (HIV), known active infectious Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC);
Female subjects who are pregnant, currently breastfeeding, planning to become pregnant;
Subjects who had experienced malignant tumors (except for adequately treated local basal cell or squamous cell carcinoma of the skin and cervical carcinoma in situ that have been cured) within the past 5 years;
Subjects who have any other conditions that are not specified in the protocol but the investigator believes that they are not suitable for inclusion in this trial.